TY - JOUR AU - Kharitonenkov, Alexei AU - Shiyanova, Tatiyana L. AU - Koester, Anja AU - Ford, Amy M. AU - Micanovic, Radmila AU - Galbreath, Elizabeth J. AU - Sandusky, George E. AU - Hammond, Lisa J. AU - Moyers, Julie S. AU - Owens, Rebecca A. AU - Gromada, Jesper AU - Brozinick, Joseph T. AU - Hawkins, Eric D. AU - Wroblewski, Victor J. AU - Li, De-Shan AU - Mehrbod, Farrokh AU - Jaskunas, S. Richard AU - Shanafelt, Armen B. T1 - FGF-21 as a novel metabolic regulator PY - 2005/06/01/ AB - Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21–transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes. JF - The Journal of Clinical Investigation JA - J Clin Invest SN - 0021-9738 DO - 10.1172/JCI23606 VL - 115 IS - 6 UR - https://doi.org/10.1172/JCI23606 SP - 1627 EP - 1635 PB - The American Society for Clinical Investigation ER -